Lesley Fallowfield|David Cella|Jack Cuzick|Stephen Francis|Gershon Y. Locker|Anthony Howell
Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)|Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)|Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)|Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)|Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)|Brighton and Sussex Medical School|Northwestern University|University of Sussex|Cancer Research UK|AstraZeneca (United Kingdom)
purpose determine quality life qol women participating arimidex tamoxifen alone combination atac adjuvant breast cancer trial first 2 years treatment patients methods total 1021 women enrolled onto qol subprotocol completed primary treatment surgery radiotherapy chemotherapy receive 5 years adjuvant treatment anastrozole n 335 tamoxifen n 347 combination n 339 patients completed functional assessment cancer therapybreast factb plus endocrine subscale es baseline 3 6 12 18 24 months disease recurrence primary end point factb trial outcome index toi secondary end point es total score analyses individual endocrine symptoms also explored results questionnaire completion approximated 85 assessments available analysis overall qol groups improved baseline 2year period significant differences toi es scores across treatment groups endocrine symptoms increased baseline 3 months groups stabilized thereafter small differences side effect profiles compared patients receiving tamoxifen patients receiving anastrozole reported significantly fewer cold sweats vaginal discharge yet vaginal dryness painful intercourse loss sexual interest conclusion two years treatment anastrozole tamoxifen combination similar overall qol impact showing gradual improvement time endocrinerelated symptoms three arms worsened initially recovered partially 2 years different symptoms experienced may assist decision making treatment supportive care needs